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Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UKExperimental and human studies indicate that macrophages play a key role within the diseased kidney
and represent a target for novel therapies. This brief review outlines the involvement and nature of
macrophages in renal disease and highlights the phenotypic plasticity of these cells and their respon-
siveness to the renal microenvironment.
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).M onocytes and macrophages are key componentsof the mononuclear phagocyte system.1 Whereas
dendritic cells are specialized for immune surveillance
and the activation of the adaptive immune system,
macrophages are highly phagocytic cells that are
involved in tissue development and homeostasis,
inﬂammation, ﬁbrosis, and tissue repair.2,3 Difﬁculties
can arise, however, as there is signiﬁcant overlap be-
tween the cell surface markers of macrophages and
dendritic cells (e.g., F4/80, CD11b, and CD11c) such
that the nomenclature can be confusing and experi-
mental data open to more than one interpretation.1,2,4
For example, the majority of resident renal mono-
nuclear phagocytes express CD11c that has often been
used as a marker of dendritic cells. However, the
analysis of renal F4/80þCD11cþ cells for cell surface
markers and function indicates that they express
scavenger receptors (CD206 and CD204) and are very
phagocytic cells with limited capacity to present anti-
gen—typical features of macrophages.5 Additional
studies highlight the fact that the kidney contains
multiple subpopulations of cells with features of den-
dritic cells or macrophages.6
During disease, the resident macrophage population
is increased by the recruitment of monocyte from
the circulation driven by chemokines such as CC che-
mokine ligand 2 and their subsequent differentiation tospondence: Jeremy Hughes, MRC Centre for Inﬂammation
rch, Queen’s Medical Research Institute, Room W2.19, 47
France Crescent, Edinburgh EH16 4TJ, UK. E-mail: jeremy.
s@ed.ac.uk
ved 27 May 2016; revised 5 August 2016; accepted 5 August
published online 12 August 2016macrophages. In addition, renal expression of the
monocyte/macrophage growth factor colony stimu-
lating factor-1 (CSF-1) is increased in the inﬂamed
kidney.7,8 CSF-1 plays an important role in mediating
the survival, proliferation, and differentiation of
monocytes and macrophages such that increased CSF-1
expression leads to signiﬁcant macrophage prolifera-
tion that expands the renal macrophage number.9–12
Macrophages encounter myriad stimuli within
normal, injured, healing, and ﬁbrotic tissues such as
hypoxia, cytokines, chemokines, reactive oxygen spe-
cies, apoptotic cells, and debris. Macrophages need to
integrate these potentially competing signals to adopt a
phenotype deemed appropriate to the situation.
Experimental in vitro and in vivo studies have shown
that macrophages may adopt a range of diverse phe-
notypes broadly categorized as the proinﬂammatory
M1 phenotype or the wound healing M2 phenotype.13
Exposure to Toll-like receptor ligands such as
pathogen-derived endotoxin or damage-associated
molecular patterns released during sterile tissue injury14
and cytokines such as interferon-g induces M1 macro-
phage polarization.M1macrophages upregulate cytotoxic
and microbicidal mediators such as tumor necrosis factor-
a and inducible nitric oxide synthase (iNOS) and may
exhibit increased expression of Ly6C and human leuko-
cyte antigen-antigen D related. Although the M1 pheno-
type is appropriate for dealingwith infective pathogens, it
is associated with tissue injury in sterile inﬂammation.
Transcription factors help regulate the genes
involved in macrophage programming. For example,
the transcription factor interferon regulatory factor
5 plays a key role in the induction of the proin-
ﬂammatory M1 phenotype such that small, interferingKidney International Reports (2016) 1, 204–209
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5 can limit M1 macrophage activation and promote M2
macrophage activation in vivo with the resultant
amelioration of tissue injury in models of cardiac and
spinal cord injury.15,16
Exposure to cytokines such as interleukin-10 and
interleukin-4, immune complexes, as well as the
ingestion of apoptotic cells, induces M2 macrophage
polarization. M2 macrophages upregulate arginase ac-
tivity and typically express increased levels of scav-
enger receptors such as CD206, CD204, and CD163.
Although M2 macrophages are anti-inﬂammatory and
termed wound healing, they are often associated with
maladaptive renal ﬁbrosis.
Macrophages may exert immunoregulatory func-
tions and cells termed regulatory macrophages (Mregs)
have been implicated in the development of tolerance
to allografts.17 Mregs express few M1 or M2 markers
with the production of interleukin-10 being key for
their immunosuppressive actions that include the in-
hibition of CD8þ T-cell responses and induction of
regulatory T cells. Recent work, albeit using a murine
vascularized cardiac transplant model, suggests that
Mreg generation requires the actions of CSF-1 and Toll-
like receptor 4 engagement.18 Mregs expressed the cell
surface marker dendritic cell-speciﬁc intercellular
adhesion molecule-3-grabbing non-integrin (CD209)
and were key to the induction of tolerance by cos-
timulatory blockade as the inhibition of these cells
abrogated tolerance.18
Despite the utility of the M1/M2 paradigm, it should
be appreciated that the biological reality is much more
complex with subtle but important differences be-
tween different activation stimuli.19–21 As a result,
many additional phenotypes will undoubtedly exist
including mixed macrophage phenotypes where M1
and M2 markers may coexist.22,23
Insights From Experimental Models of Renal
Disease and Macrophage Depletion Studies
In an attempt to mimic human disease, investigators
have developed multiple experimental models of renal
injury in rodents that can be employed in mice deﬁ-
cient in chemokines (CC chemokine ligand 2) or che-
mokine receptors (CC chemokine receptor 2 and CX3C
chemokine receptor 1) involved in monocyte/macro-
phage recruitment. This strategy has demonstrated that
monocytes/macrophages caused kidney injury in mul-
tiple experimental models including nephrotoxic
nephritis,24 diabetic nephropathy,25 and renal ischemia-
reperfusion injury (IRI).26
Liposomal clodronate is cytotoxic after uptake by
cells and has been a useful tool to deplete monocytes/
macrophages in various organs as it targets theKidney International Reports (2016) 1, 204–209phagocytic macrophage. Studies have shown renal
protection after clodronate-mediated macrophage
depletion in multiple models of kidney injury or dis-
ease including cystic renal disease.27–31 The develop-
ment of transgenic mice in which the expression of the
human or simian diphtheria toxin receptor (DTR) is
under the control of the CD11b promoter has allowed
the relative selective depletion of CD11bþ monocytes
and macrophages by the administration of DT to
mice.32 This system has demonstrated reduced injury
or ﬁbrosis after monocyte/macrophage depletion in
models of ﬁbrosis,33 nephrotoxic nephritis,34 and mu-
rine transplantation.35 Interestingly, no protection was
evident in murine renal IRI36 although the addition of
clodronate to DT conferred protection.37
It is important to bear in mind that macrophages are
not always injurious or proﬁbrotic as the critical
reparative role of the macrophage has been highlighted
by studies of macrophage depletion using liposomal
clodronate or CD11b/DTR mice in the reparative phase
of the renal IRI model. This phase is characterized by
the restoration of renal function and tubular repair,
and macrophage depletion is highly detrimental as it
results in increased mortality, prolonged injury, and
failure of tubular repair.38–41 During renal repair,
macrophages are an important source of mediators such
as Wnt7b and IL-22 that promote tubular epithelial
proliferation.40,42
Lastly, it should be noted that few studies have
attempted to dissect the roles of resident macrophages
versus inﬁltrating monocyte-derived macrophages to
determine which macrophage population is key to
injury and ﬁbrosis as interventions to deplete macro-
phages typically exert effects on both populations. To
explore this question, Lin et al.43 used bone marrow
transplantation to generate chimeric CD11b/DTR mice
such that the administration of DT would either deplete
resident renal macrophages or inﬁltrating monocyte-
derived macrophages. These studies used the model
of unilateral ureteric obstruction that exhibits marked
interstitial ﬁbrosis with a dramatic macrophage inﬁl-
trate. DT-induced depletion of DTRþ inﬁltrating
monocyte-derived macrophages was markedly anti-
ﬁbrotic. In contrast, the targeted depletion of DTRþ
resident macrophages did not affect ﬁbrosis despite the
fact that they constituted up to 40% of the total
macrophage population.
Although the majority of patients with signiﬁcant
renal disease are elderly, the vast majority of experi-
mental rodent studies are undertaken in young animals.
It is pertinent that aged mice develop much worse acute
kidney injury after renal IRI44,45 with the induction of
the cytoprotective enzyme hemeoxygenase-1 being less
robust compared with young mice. The administration205
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Figure 1. Macrophage phenotype within the diseased kidney. Renal
injury and inﬂammation leads to the release of proinﬂammatory
mediators including chemokines, cytokines, and damage-associated
molecular patterns (DAMPs). These and other mediators result in the
induction of a proinﬂammatory cytotoxic M1 macrophage. Upregu-
lated tubular expression of colony stimulating factor-1 (CSF-1)
expression induces macrophage proliferation that may promote
ongoing renal injury in the presence of persistent inﬂammation.
During repair, various mediators including interleukin (IL)-10,
apoptotic cells, and the growth factors CSF-1 and granulocyte
macrophage (GM)-CSF promote the phenotypic switch to anti-
inﬂammatory wound healing M2 macrophages that may promote
the restoration of tubular integrity by releasing mitogens such as
Wnt7b and IL-22.
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strongly protected aged mice from renal IRI with
monocyte/macrophage hemeoxygenase-1 expression
being critical. Other macrophage functions such as the
phagocytosis of apoptotic cells have been noted to be
abnormal in aging mice46 with a defect in both resident
and recruited macrophage phagocytosis evident. It is
thus likely that the monocytes and macrophages of
elderly patients may behave differently to younger
individuals.
Although the number and phenotype of endogenous
macrophages may be the target of interventions, it is
also of interest that the exogenous administration of
anti-inﬂammatory or M2 macrophages can ameliorate
both acute and chronic experimental disease.47–49
The Regulation of Macrophage Phenotypes
In Vivo
It thus appears that macrophages may be cytotoxic
(M1), reparative (M2), or proﬁbrotic (M2) within the
kidney. An important question that has been
addressed recently is whether these differing M1/M2
macrophage phenotypes are directly derived from
either resident macrophages or recruited monocytes or
whether macrophages can change their phenotype
within the kidney as a result of changes in the renal
microenvironment. Lee et al.39 performed elegant
adoptive transfer experiments involving the adminis-
tration of ﬂuorescently labeled bone marrow-derived
macrophages programmed in vitro to adopt an M1
phenotype to mice shortly after the induction of renal
IRI. The labeled cells were retrieved at later time
points and were found to have an M2 phenotype as
they exhibited the downregulation of iNOS expression
and the upregulation of CD206 expression. This study
indicated that macrophage phenotype is dynamic and
can evolve during the injury and repair phase of renal
injury (Figure 1).
Further work has highlighted the importance of the
renal expression of macrophage growth and differen-
tiation factors by tubular epithelial cells in the bene-
ﬁcial reprogramming of proinﬂammatory M1
macrophages to reparative M2 macrophages with a role
for both CSF-1 (also termed macrophage-colony stim-
ulating factor)50,51 and granulocyte macrophage-CSF.52
The effect of CSF-1 on M1 macrophage reprogram-
ming may be via the induction of microRNA-2453
although renal data are lacking at present.
In the light of the beneﬁcial role of CSF-1 in
modulating the phenotype of macrophages, it is
intriguing that strategies to inhibit the function of CSF-
1 using function blocking antibodies or drugs that
target activation of the CSF-1 receptor have been
shown to be protective in a wide range of experimental206models.54–58 These studies suggest that reducing
macrophage proliferation and number is beneﬁcial in
situations where there are excessive numbers of mac-
rophages driving injury or ﬁbrosis. In contrast, the
exogenous administration of CSF-1 after experimental
murine IRI signiﬁcantly improved renal repair, sug-
gesting that augmenting the population of macro-
phages involved in renal repair is highly beneﬁcial.59
Recent work has suggested an important role for
retinoic acid in modulating macrophage phenotype via
the direct inhibition of M1 macrophages and the pro-
motion of tubular cell induction of M2 macrophages,
indicating that there are multiple pathways to manip-
ulate macrophage phenotype.60
Macrophages—Key Players in Human Disease
Macrophages are present in human renal diseases,
including diabetes,61,62 polycystic kidney disease,
kidney allograft rejection,63 chronic allograft ne-
phropathy,64,65 and acute kidney injury.22,65 Studies
have demonstrated a strong association between the
extent of macrophage inﬁltration and functional
outcome.66 A recent study of pediatric kidney trans-
plant recipients with chronic allograft nephropathy
demonstrated CD163þ M2 macrophages in ﬁbrotic
areas of the kidney with CD163þ cell number corre-
lating with interstitial ﬁbrosis and renal function.64
Interestingly, urine CD163 levels also correlated with
ﬁbrosis, suggesting the potential for using urineKidney International Reports (2016) 1, 204–209
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renal scarring. Similarly, in a study of 1-year renal
transplant biopsies from adult transplant recipients,
the numbers of CD206þ macrophages correlated with
both ﬁbrosis and renal function at 3 years after trans-
plantation.67 Additional recent work highlights the
involvement of macrophages in lupus nephritis68 with
the number of interstitial CD68þ macrophages corre-
lating with renal function and ﬁbrosis. A minority of
macrophages were iNOSþ M1 macrophages with the
majority being positive for the M206 markers CD206
and CD163. The proportions of iNOSþ, CD206, or
CD163 varied between glomerular and interstitial
compartments and between classes of lupus nephritis.
The predominance of M2 macrophages over M1 mac-
rophages may reﬂect patients undergoing a renal bi-
opsy at a later stage of disease than is usual in
experimental models of lupus nephritis as well as the
potential effects of drug treatment such as steroids that
can induce an M2 phenotype.
Potential Therapeutic Approaches to Target
Macrophages
In view of the complexity of macrophage phenotypes
and their involvement in multiple aspects of kidney
disease (acute kidney injury, renal repair, glomerulo-
nephritis, ﬁbrosis, etc.), the timing of interventions
directed to manipulate macrophage phenotypes or
numbers will need to be carefully considered. Some
therapies currently in use will exert effects on macro-
phages. For example, glucocorticoids increase the
phagocytic capabilities of macrophages and induce an
anti-inﬂammatory phenotype.69 Potential strategies to
limit macrophage numbers include the inhibition of
chemokines involved in the recruitment of monocytes to
the kidney, and there are clinical trials in progress that
are targeting the CCL2/CCR2 axis in patients with renal
disease such as diabetic nephropathy. There is also po-
tential for the inhibition of growth factors such as CSF-1
in situations where macrophages are driving injury and/
or ﬁbrosis or the administration of exogenous CSF-1 to
bolster a reparative macrophage population. Although
macrophage cell therapy for inﬂammatory renal disease
has not been undertaken thus far, the effect of admin-
istering donor-derived Mregs generated in vitro was
examined in 2 patients who underwent live donor
kidney transplantation.70 Graft function remained sta-
ble over 3 years with the patients being maintained on
tacrolimus monotherapy. In addition, the peripheral
blood gene signature of these patients was similar to that
found in tolerant patients. The administration of Mregs
is now being tested in the active ONE Study Mreg Trial
that aims to increase tolerance in living donor transplant
recipients (NCT02085629).Kidney International Reports (2016) 1, 204–209Conclusion
Macrophages are remarkably versatile cells and,
although they may assist tissue remodeling, they are
often associated with tissue injury and disease pro-
gression. A deeper understanding of the cellular and
molecular mechanisms that mediate the diverse func-
tions of macrophages in renal disease should allow the
development of novel therapies that may have appli-
cability to multiple organs.
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